Page last updated: 2024-11-07

aldosterone and Glycosuria

aldosterone has been researched along with Glycosuria in 12 studies

Glycosuria: The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-199010 (83.33)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amin, NB1
Wang, X1
Mitchell, JR1
Lee, DS1
Nucci, G1
Rusnak, JM1
Ackermann, TF1
Boini, KM1
Völkl, H1
Bhandaru, M1
Bareiss, PM1
Just, L1
Vallon, V1
Amann, K1
Kuhl, D1
Feng, Y1
Hammes, HP1
Lang, F1
Gilli, P1
De Paoli Vitali, E1
Tataranni, G1
Farinelli, A1
Kleinberger, G1
Suzuki, H1
Nakagawa, K1
Nakayama, H1
Kunita, H1
Hata, S1
Hori, S2
Masumura, S2
Ono, K2
Sato, Y1
Liddle, GW1
Lindheimer, MD1
Katz, AI1
Sims, EA1
Schultis, K1
Geser, CA1
Wagner, E1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequa[NCT01096667]Phase 2194 participants (Actual)Interventional2010-05-17Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Baseline 24-hour Average Systolic Blood Pressure (SBP)

Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM). (NCT01096667)
Timeframe: 24 hours

InterventionmmHg (Mean)
Placebo136.11
Ertugliflozin 1 mg133.13
Ertugliflozin 5 mg135.08
Ertugliflozin 25 mg135.59
HCTZ 12.5mg139.55

Baseline 24-hour Average Urinary Glucose Excretion

Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). (NCT01096667)
Timeframe: 24 hours

Interventiongrams/day (Mean)
Placebo13.35
Ertugliflozin 1 mg9.97
Ertugliflozin 5 mg8.04
Ertugliflozin 25 mg17.56
HCTZ 12.5mg6.96

Baseline Fasting Plasma Glucose (FPG)

For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline

Interventionmg/dL (Mean)
Placebo169.47
Ertugliflozin 1 mg158.38
Ertugliflozin 5 mg158.29
Ertugliflozin 25 mg172.03
HCTZ 12.5mg156.87

Baseline Seated, Triplicate Trough DBP

Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures. (NCT01096667)
Timeframe: Baseline

InterventionmmHg (Mean)
Placebo84.89
Ertugliflozin 1 mg83.08
Ertugliflozin 5 mg83.79
Ertugliflozin 25 mg83.89
HCTZ 12.5mg84.72

Baseline Seated, Triplicate Trough Heart Rate

Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures. (NCT01096667)
Timeframe: Baseline

Interventionbeats per minute (Mean)
Placebo77.07
Ertugliflozin 1 mg78.73
Ertugliflozin 5 mg77.30
Ertugliflozin 25 mg75.63
HCTZ 12.5mg77.97

Baseline Seated, Triplicate Trough SBP

Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures. (NCT01096667)
Timeframe: Baseline

InterventionmmHg (Mean)
Placebo135.17
Ertugliflozin 1 mg134.23
Ertugliflozin 5 mg137.31
Ertugliflozin 25 mg135.25
HCTZ 12.5mg138.07

Change From Baseline in FPG at Week 2

For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 2

Interventionmg/dL (Least Squares Mean)
Placebo-5.44
Ertugliflozin 1 mg-10.98
Ertugliflozin 5 mg-22.45
Ertugliflozin 25 mg-32.03
HCTZ 12.5mg3.21

Change From Baseline in FPG at Week 4

For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 4

Interventionmg/dL (Least Squares Mean)
Placebo4.39
Ertugliflozin 1 mg-13.70
Ertugliflozin 5 mg-30.41
Ertugliflozin 25 mg-31.03
HCTZ 12.5mg3.79

Change From Baseline in Seated, Triplicate Trough DBP at Week 4

Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo0.30
Ertugliflozin 1 mg-0.90
Ertugliflozin 5 mg-0.75
Ertugliflozin 25 mg-2.71
HCTZ 12.5mg-2.54

Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4

Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4

Interventionbeats per minute (Least Squares Mean)
Placebo2.34
Ertugliflozin 1 mg-1.86
Ertugliflozin 5 mg1.22
Ertugliflozin 25 mg-1.51
HCTZ 12.5mg-0.99

Change From Baseline in Seated, Triplicate Trough SBP at Week 4

Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo1.24
Ertugliflozin 1 mg-2.77
Ertugliflozin 5 mg-5.92
Ertugliflozin 25 mg-4.96
HCTZ 12.5mg-3.13

Change From Baseline on 24-hour Average DBP at Week 4

Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo0.77
Ertugliflozin 1 mg-1.89
Ertugliflozin 5 mg-2.34
Ertugliflozin 25 mg-1.50
HCTZ 12.5mg-1.42

Change From Baseline on 24-hour Average Heart Rate at Week 4

Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionBeats per minute (Least Squares Mean)
Placebo1.00
Ertugliflozin 1 mg-1.22
Ertugliflozin 5 mg1.07
Ertugliflozin 25 mg-1.39
HCTZ 12.5mg-0.56

Change From Baseline on 24-hour Average SBP at Week 4

Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF). (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo0.26
Ertugliflozin 1 mg-2.71
Ertugliflozin 5 mg-3.73
Ertugliflozin 25 mg-3.42
HCTZ 12.5mg-2.95

Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4

Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4

Interventiongrams/day (Least Squares Mean)
Placebo4.15
Ertugliflozin 1 mg46.33
Ertugliflozin 5 mg64.54
Ertugliflozin 25 mg74.49
HCTZ 12.5mg-0.48

Change From Baseline on Daytime Average DBP at Week 4

Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo0.87
Ertugliflozin 1 mg-2.12
Ertugliflozin 5 mg-1.88
Ertugliflozin 25 mg-1.77
HCTZ 12.5mg-1.69

Change From Baseline on Daytime Average Heart Rate at Week 4

Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionBeats per minute (Least Squares Mean)
Placebo1.58
Ertugliflozin 1 mg-1.80
Ertugliflozin 5 mg1.10
Ertugliflozin 25 mg-1.07
HCTZ 12.5mg-0.06

Change From Baseline on Daytime Average SBP at Week 4

Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo0.82
Ertugliflozin 1 mg-2.88
Ertugliflozin 5 mg-3.61
Ertugliflozin 25 mg-4.17
HCTZ 12.5mg-3.10

Change From Baseline on Nighttime Average DBP at Week 4

Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo1.02
Ertugliflozin 1 mg-1.48
Ertugliflozin 5 mg-2.52
Ertugliflozin 25 mg-0.84
HCTZ 12.5mg-0.55

Change From Baseline on Nighttime Average Heart Rate at Week 4

Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionBeats per minute (Least Squares Mean)
Placebo-0.18
Ertugliflozin 1 mg-0.15
Ertugliflozin 5 mg1.43
Ertugliflozin 25 mg-1.99
HCTZ 12.5mg-1.24

Change From Baseline on Nighttime Average SBP at Week 4

Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4

InterventionmmHg (Least Squares Mean)
Placebo-0.29
Ertugliflozin 1 mg-2.48
Ertugliflozin 5 mg-3.47
Ertugliflozin 25 mg-2.31
HCTZ 12.5mg-2.30

Number of Participants Who Discontinued Study Drug Due to an AE

An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE. (NCT01096667)
Timeframe: Up to 28 days (treatment period)

InterventionParticipants (Number)
Placebo0
Ertugliflozin 1 mg0
Ertugliflozin 5 mg0
Ertugliflozin 25 mg1
HCTZ 12.5mg0

Number of Participants Who Experienced an Adverse Event (AE)

An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. (NCT01096667)
Timeframe: Up to 63 days (including run-in, treatment period, and follow-up)

InterventionParticipants (Number)
Placebo9
Ertugliflozin 1 mg8
Ertugliflozin 5 mg15
Ertugliflozin 25 mg12
HCTZ 12.5mg10

Baseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)

Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours

,,,,
InterventionmmHg (Mean)
24-hrDaytimeNighttime
Ertugliflozin 1 mg78.6781.7772.05
Ertugliflozin 25 mg80.3683.5973.28
Ertugliflozin 5 mg80.1883.4773.05
HCTZ 12.5mg82.6685.8775.76
Placebo81.8985.3274.24

Baseline 24-hour, Daytime and Nightime Average Heart Rate

Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours

,,,,
Interventionbeats per minute (Mean)
24-hrDaytimeNighttime
Ertugliflozin 1 mg80.7483.7474.44
Ertugliflozin 25 mg79.4182.1873.49
Ertugliflozin 5 mg79.6882.7173.16
HCTZ 12.5mg79.0881.9573.03
Placebo81.1184.4374.05

Baseline Average Daytime and Nighttime SBP

Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Daytime: 16 hours; Nighttime: 8 hours

,,,,
InterventionmmHg (Mean)
DaytimeNighttime
Ertugliflozin 1 mg136.85125.15
Ertugliflozin 25 mg139.56127.13
Ertugliflozin 5 mg138.89126.37
HCTZ 12.5mg143.32131.68
Placebo139.95127.54

Reviews

3 reviews available for aldosterone and Glycosuria

ArticleYear
[Influence of insulinfree rehydration on diabetic derangements (author's transl)].
    Wiener klinische Wochenschrift, 1980, Sep-12, Volume: 92, Issue:17

    Topics: Acidosis; Adolescent; Adult; Aged; Aldosterone; Blood Glucose; C-Peptide; Diabetes Mellitus; Electro

1980
[The effect of drugs on the endocrine function tests (author's transl)].
    Rinsho byori. The Japanese journal of clinical pathology, 1974, Volume: 22, Issue:Suppl

    Topics: Adrenocorticotropic Hormone; Aldosterone; Antithyroid Agents; Biogenic Amines; Blood Glucose; Drug I

1974
Renal function in normal pregnancy.
    Clinical obstetrics and gynecology, 1968, Volume: 11, Issue:2

    Topics: Aldosterone; Blood Urea Nitrogen; Circadian Rhythm; Estradiol; Female; Glomerular Filtration Rate; G

1968

Trials

1 trial available for aldosterone and Glycosuria

ArticleYear
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Aldosterone; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambu

2015

Other Studies

8 other studies available for aldosterone and Glycosuria

ArticleYear
SGK1-sensitive renal tubular glucose reabsorption in diabetes.
    American journal of physiology. Renal physiology, 2009, Volume: 296, Issue:4

    Topics: Absorption; Age Factors; Aldosterone; Animals; Biological Transport; Blood Glucose; Body Weight; Cre

2009
ALDOSTERONE and steroid glycosuria in the cat.
    Nutrition reviews, 1958, Volume: 16, Issue:6

    Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Cats; Fludrocortisone; Glycosuria; Humans

1958
Exercise-induced urinary abnormalities in long-distance runners.
    International journal of sports medicine, 1984, Volume: 5, Issue:5

    Topics: Acetylglucosaminidase; Adolescent; Adult; Aldosterone; Electrolytes; Female; gamma-Glutamyltransfera

1984
Effect of aldosterone on angiotensin-induced glycosuria.
    Mie medical journal, 1969, Volume: 19, Issue:1

    Topics: Aldosterone; Angiotensin II; Animals; Glycosuria; Hyperglycemia; Injections, Intravenous; Rabbits; R

1969
Mechanism of angiotensin-induce glycosuria.
    Mie medical journal, 1969, Volume: 19, Issue:1

    Topics: Aldosterone; Angiotensin II; Animals; Blood Glucose; Epinephrine; Glycosuria; Hyperglycemia; Injecti

1969
Proceedings: Blueprints for the solution of three endocrinological enigmas. The Sir Henry Dale Lecture for 1973.
    The Journal of endocrinology, 1973, Volume: 59, Issue:2

    Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Blood Glucose; Ca

1973
Renal function in pregnancy.
    Obstetrics and gynecology annual, 1972, Volume: 1

    Topics: Aldosterone; Angiotensin II; Catecholamines; Estrogens; Female; Glomerular Filtration Rate; Glycosur

1972
The postoperative carbohydrate, nitrogen, fat and electrolyte metabolism: aldosterone-blocking agent effect.
    Minnesota medicine, 1970, Volume: 53, Issue:10

    Topics: Adolescent; Aldosterone; Blood Glucose; Fatty Acids; Glucose; Glycosuria; Humans; Ketone Bodies; Mal

1970